Meeting Close
EASL LiverTree™, Elisabetta BUGIANESI, 227298
Transplantation for NAFLD - outcomes and complications
EASL LiverTree™, Paolo Muiesan, 227295
Clinical Case V - Patient with decompensated NASH
EASL LiverTree™, Patrizia Burra, 227293
Assessing cost effectiveness of pharmacotherapy - how will it work in NAFLD?
EASL LiverTree™, Martin Harker, 227285
Sequential or combination therapy - what challenges does this pose?
EASL LiverTree™, Aditi Saxena, 227284
Licensing end-points - update from AASLD/EASL end-points meeting 2018
EASL LiverTree™, Arun Sanyal, 227283
Anti-fibrotic agents
EASL LiverTree™, Fabio Marra, 227274
Mechanisms and pathways of hepatocyte cell-death in steatohepatitis
EASL LiverTree™, Jérémie Gautheron, 227273
Targeting lipotoxicity
EASL LiverTree™, Chuhan Chung, 227272
Round-table discussion & Consensus Statement III: How should we manage patients with NAFLD/NASH in 2018? What lifestyle advice should we give?
EASL LiverTree™, Session Speakers, 231716
Consideration of metabolic surgery and metabolic endoscopy?
EASL LiverTree™, Sigal Fishman, 227265
Clinical Case IV - illustration of evolution of case to cirrhosis to include T2DM and rising weight
EASL LiverTree™, Elisabetta BUGIANESI, 227264
Lifestyle management including nutrition and exercise
EASL LiverTree™, Mathias PLAUTH, 227263
Clinical Case III - case showing evolution to confirmed NASH
EASL LiverTree™, Elisabetta BUGIANESI, 227262
Round-table discussion & Consensus Statement I: - Assessing patient symptoms in NASH in trial and in practice
EASL LiverTree™, Session Speakers, 231715
Patient Reported Outcome Measures - the regulatory perspective
EASL LiverTree™, Elmer Schabel, 227255
Role of patient organizations in progression from NAFLD to NASH and further
EASL LiverTree™, Marko Korenjak, 227254
Patient reported outcome measures in NASH and science behind the symptoms
EASL LiverTree™, Zobair Younossi, 227253
How patients feel: Assessing symptoms in patients with NASH: Chair
EASL LiverTree™, Salvador AUGUSTIN, 227251
State-of-the-art: Carcinogenesis in NASH
EASL LiverTree™, Jessica Zucman-Rossi, 227250
Best animal models for NASH research - view from industry
EASL LiverTree™, Keld Fosgerau, 227249
Mechanisms of fibrogenesis in NASH
EASL LiverTree™, Detlef SCHUPPAN, 227248
Gut and the liver
EASL LiverTree™, Herbert Tilg, 227247
Insulin resistance and lipotoxicity
EASL LiverTree™, Amalia Gastaldelli, 227246
Promises and limits of non-invasive methods in NASH
EASL LiverTree™, Jérôme Boursier, 227241
Clinical Case II - evolution of identified case + use of non-invasive modalities
EASL LiverTree™, Emmanuel Tsochatzis, 227240
Case identification in diabetes clinics : where do we stand so far ?
EASL LiverTree™, Roy Taylor, 227239
Clinical Case I - how do cases present in the community+ Exemplar case illustrating challenge how to decide which patients need specialist input
EASL LiverTree™, Emmanuel Tsochatzis, 227238
The clinical picture of NAFLD/NASH: Round-table discussion
EASL LiverTree™, Session Speakers, 227235
The current policy on NAFLD in Europe - results from the EILF NAFLD policy review
EASL LiverTree™, Frank Tacke, 227234
Natural history and use of large data to risk stratify
EASL LiverTree™, Quentin Mark Anstee, 227233
Paediatric NAFLD: the future burden of NASH including the risk of HCC linked to obesity during childhood
EASL LiverTree™, Valerio Nobili, 227232
Health care burden of NAFLD and NASH
EASL LiverTree™, Jacob George, 227231
Global overview of obesity and population strategies to tackle it
EASL LiverTree™, Harry Rutter, 227230
Welcome and introductory remarks
EASL LiverTree™, Prof. Frank Tacke & Philip N. Newsome, 233814
Closing remarks: Chair
EASL LiverTree™, Prof. Agustín Albillos, Dr Maria Rescigno and Dr. Andrea De Gottardi, 221455
Designing clinical trials targeting the gut microbiota
EASL LiverTree™, Onno Holleboom, 218993
Drug- and xenobiotic metabolism and the gut microbiota
EASL LiverTree™, Francesca Romana Ponziani, 218992
Unmet technical and methodological needs
EASL LiverTree™, Jingyuan Fu, 218991
Industry point of view: FXR agonists or antagonists
EASL LiverTree™, Luciano Adorini, 218987
Modulating the gut-liver axis in portal hypertension
EASL LiverTree™, Andrea De Gottardi, 218985
Gut microbiota, intestinal glutaminase and hepatic encephalopathy
EASL LiverTree™, Manuel Romero Gomez, 218984
Industry point of view: Impact of ingested bacteria on human gut microbiota
EASL LiverTree™, Muriel Derrien, 218981
Nanoporous carbon adsorbent to modify liver disease
EASL LiverTree™, Rajiv Jalan, 218980
The Regenerating Liver is Vulnerable to Lymph circulating Intestinal Bacteria
EASL LiverTree™, Manuel Jakob, 218979
Fecal transplantation in cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 218977
Next generation probiotics
EASL LiverTree™, Philippe Langella, 218976
Gut microbiota and host immunity interaction in health and disease
EASL LiverTree™, Harry Sokol, 218973
Industry point of view: BiomX, Targeting Chronic Microbiome Diseases by Phages
EASL LiverTree™, Eyal Weinstock, 218972
Industry point of view: Targeting the duodenum for metabolic gain
EASL LiverTree™, David Maggs, 218971
Industry point of view: Synthetic biotic medicines in liver disease
EASL LiverTree™, Caroline Kurtz, 218970
Assessment of intestinal permeability and translocation. Endoscopy and imaging tools
EASL LiverTree™, Reiner Wiest, 218969
Gnotobiotic animal models
EASL LiverTree™, Siegfried Hapfelmeier, 218968
Intestinal barrier failure in cirrhosis: impact on complications
EASL LiverTree™, Agustin Albillos, 218964
Interaction between intestine and liver in alcoholic liver disease
EASL LiverTree™, Jasmohan S Bajaj, 218963
The gut microbiota in NAFLD and associated metabolic disorders
EASL LiverTree™, Nathalie Delzenne, 218962
Inhibition of hepatic bile acid uptake prolongs bile acid signalling, leading to reduced adiposity and increased GLP-1 secretion
EASL LiverTree™, Joanne Donkers, 218960
Intestinal mucus and gut-vascular barrier in liver cirrhosis: Entry sites for bacterial translocation from the gut to the liver independent from portal hypertension and lymphatic route
EASL LiverTree™, Marcel Sorribas, 218959
Industry point of view: Ammonia and metabolite uptake of VS-01
EASL LiverTree™, Vincent Forster, 218958
Antibiotics to Modulate the Gut Liver Axis and RifSys RCT Preliminary Metagenomics Data
EASL LiverTree™, Vishal Patel, 218957
Bile acid signaling and the FXR pathway
EASL LiverTree™, Michael Trauner, 218954
Liver and gut-derived inflammation in the pathophysiology of ACLF
EASL LiverTree™, Jonel Trebicka, 218950
The gut-liver axis in the control of hepatobiliary malignancies
EASL LiverTree™, Gianluca Svegliati-Baroni, 218949
Contribution of intestinal inflammation and dysbiosis to cholestatic liver disease
EASL LiverTree™, Johannes R. Hov, 218948
Disturbances of gut microbiota on liver inflammation and fibrosis
EASL LiverTree™, Bernd Schnabl, 218947
Bile acid signaling in the gut-liver axis
EASL LiverTree™, Oihane Garcia-Irigoyen, 218944
Circulation and homing of immune cells
EASL LiverTree™, David Adams, 218943
Structure and function of the intestinal barrier
EASL LiverTree™, Maria Rescigno, 218942
Opening and state-of-the-art: Chair
EASL LiverTree™, Prof. Agustín Albillos, Dr Maria Rescigno and Dr. Andrea De Gottardi, 221454
Sheila Sherlock 100th year anniversary ILC 2018 wrap up session: Closing
EASL LiverTree™, Tom Karlsen, 212777
Complications of cirrhosis and liver transplantation
EASL LiverTree™, Dominique Thabut Damais, 210807
Hepatocellular carcinoma
EASL LiverTree™, Fabio Piscaglia, 210806
Metabolic and cholestatic diseases
EASL LiverTree™, Herbert Tilg, 210805
Sheila Sherlock 100th year anniversary ILC 2018 wrap up session: Chair
EASL LiverTree™, Massimo Pinzani, 210802
Viral hepatitis
EASL LiverTree™, Maria Buti, 210804
Management of AKI in cirrhosis: place of terlipressin, hemofiltration and combined liver and kidney transplantation
EASL LiverTree™, Mitra Nadim, 210792
Liver transplantation in patients with alcohol-related liver disease
EASL LiverTree™, Alexandre Louvet, 210797
Perspectives of personalized medicine in primary liver cancer
EASL LiverTree™, Eric Raymond, 210786
Targeting the gut-liver axis for liver diseases
EASL LiverTree™, Herbert Tilg, 210801
Predicting renal recovery versus non recovery after liver transplantation: the role of kidney biomarkers
EASL LiverTree™, claire FRANCOZ, 210791
Management of alcohol dependence and other co-dependencies
EASL LiverTree™, Lorenzo Leggio, 210796
Viral hepatitis and the community: Addressing the continuum of care: Panel Discussion
EASL LiverTree™, Session Speakers, 212774
From gut to the liver: inflammatory signaling
EASL LiverTree™, Robert Schwabe, 210800
MPP model to expand access to meds
EASL LiverTree™, Ludmila Maistat, 210781
The role of the hepatologist
EASL LiverTree™, Bruno Sangro, 210785
New insights in the mechanisms: interactions between kidney circulatory changes, systemic circulatory changes, systemic inflammation and parenchymal kidney changes
EASL LiverTree™, Paolo Angeli, 210790
Managing obesity and other comorbidities in alcohol-related liver disease
EASL LiverTree™, Arun Sanyal, 210795
Linkage to care
EASL LiverTree™, Philip Bruggmann, 210780
The role of the medical oncologist
EASL LiverTree™, Lorenza Rimassa, 210784
Prevalence and prognostic implications of impaired renal function in cirrhosis: beyond definitions and classifications
EASL LiverTree™, Guadalupe Garcia-Tsao, 210789
Symposium: Multidisciplinary management of alcoholic liver disease: Chair
EASL LiverTree™, Marsha Morgan, 210793
New EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
EASL LiverTree™, Mark Thursz, 210794
Pathogenicity of disturbances in the gut-liver axis
EASL LiverTree™, Bernd Schnabl, 210799
EASL-ESMO Symposium: Collaboration between medical oncologists and hepatologists to boost therapeutic advances in liver cancer: Chair
EASL LiverTree™, Prof. Jean-Luc Raoul & Prof. Peter Galle, 214369
Streamlining diagnostics
EASL LiverTree™, Francesco Marinucci, 210779
Access to care in precarious populations (awareness, stigma, self-stigma)
EASL LiverTree™, Nicola Perry, 210778
HCV epidemic EE and Central Asia: current situation
EASL LiverTree™, Olga Golubovskaya, 210775
Elements for an effective response to viral hepatitis in PWID (EU28)
EASL LiverTree™, Thomas Seyler, 210774
The Georgia experience: lessons for viral hepatitis elimination
EASL LiverTree™, John Ward, 210773
Introduction, agenda, setting the goals
EASL LiverTree™, Francesco Negro, 210771
Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing Phase 2 study.
EASL LiverTree™, Christoph Schramm, 210767
JKB-121 in Patients with Nonalcoholic Steatohepatitis: A Phase 2 Double Blind Randomized Placebo Control Study
EASL LiverTree™, Manal Abdelmalek, 210766
The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
EASL LiverTree™, Jens Ricke, 210765
Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatment-naive chronic hepatitis B (CHB) patients without cirrhosis
EASL LiverTree™, Fabien Zoulim, 210764
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated
EASL LiverTree™, Edward Gane, 210763
NGM282, an Engineered Analogue of FGF19, Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
EASL LiverTree™, Gideon Hirschfield, 210762
A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
EASL LiverTree™, Naga Chalasani, 210761
EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy: Panel Discussion
EASL LiverTree™, Session Speakers, 212773
The road ahead – will novel HBV treatments enter clinics soon? Antiviral therapies
EASL LiverTree™, Man-Fung Yuen, 210758
Civil society perspective on the revised 2018 WHO Guidelines and access to treatment
EASL LiverTree™, Giten Khwairakpam, 210749
Immunotherapy and emerging targets in phase 3
EASL LiverTree™, Sandrine Faivre, 210753
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Panel Discussion
EASL LiverTree™, Session Speakers, 212772
The Cardiologist perspective
EASL LiverTree™, Christopher D. Byrne, 210741
The road ahead – will novel HBV treatments enter clinics soon? Immunological therapies
EASL LiverTree™, Mala Maini, 210757
Revised 2018 WHO Guidelines for the care and treatment of persons with chronic HCV
EASL LiverTree™, Dr. Marc Bulterys & Dr. Saeed Sadiq Hamid, 214370
The General Practicionner perspective
EASL LiverTree™, Rachel Pryke, 210740
Systemic therapy: Current status and lessons learned from success and failure
EASL LiverTree™, Maria Reig, 210752
Clinicians as key partners in meeting the 2030 elimination goals
EASL LiverTree™, Rakesh Aggarwal, 210746
Stopping NUC therapy before HBsAg loss – a good idea?
EASL LiverTree™, Florian van Boemmel, 210756
Ablation and transarterial approaches. Efficacy vs benefit
EASL LiverTree™, Jens Ricke, 210751
Fighting HBV with limited resources: The global perspective
EASL LiverTree™, Maud Lemoine, 210755
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Chair
EASL LiverTree™, Laurent Castera, 210736
The Hepatologist perspective
EASL LiverTree™, Lawrence Serfaty, 210738
Monitoring progress towards the elimination of viral hepatitis
EASL LiverTree™, Yvan Hutin, 210744
Short review of unmet needs in HCC treatment
EASL LiverTree™, Jordi Bruix, 210750
Introduction: Aims and open questions in HBV management
EASL LiverTree™, Jörg Petersen, 210754
EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy: Introduction
EASL LiverTree™, Prof. Tom Hemming Karlsen & Gottfried Hirnschall, 214368
Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with Sofosbuvir-based regimens
EASL LiverTree™, Alessandra Mangia, 210732
A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria
EASL LiverTree™, Eliane Sardh, 210730
Award ceremony 2
EASL LiverTree™, Session Speakers, 210729
Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
EASL LiverTree™, Jasmohan S Bajaj, 210728
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
EASL LiverTree™, Stephen Harrison, 210727
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis c: the Navigator-II study
EASL LiverTree™, Roberta D'Ambrosio, 210726
Radioembolization in HCC: Still waiting for positive RCTs?
EASL LiverTree™, Sherrie Bhoori, 210723
Symposium: NAFLD management in 2018: Panel Discussion
EASL LiverTree™, Session Speakers, 212529
Role of surgery in non-early HCC patients
EASL LiverTree™, Tanto Cheung, 210722
Introducing the EASL Nurses CAG
EASL LiverTree™, Michelle Clayton, 210705
Clinical impact of SVR in patients with Hepatitis C
EASL LiverTree™, Sabela Lens, 210709
Pharmacological therapy: What to expect in the near future?
EASL LiverTree™, Sven Francque, 210714
Life style intervention: What are the needs?
EASL LiverTree™, Kate Hallsworth, 210713
Diagnostic algorithm of HCC in Japan
EASL LiverTree™, Ryosuke Tateishi, 210720
End of life care planning in people with chronic liver disease
EASL LiverTree™, Elsebeth Elmstrøm Holst Jensen, 210704
Post SVR follow-up in chronic HCV: When is it necessary?
EASL LiverTree™, Stefan Zeuzem, 210708
Non-invasive techniques: Current role in diagnosis and follow-up
EASL LiverTree™, Jérôme Boursier, 210712
Changing pattern of HCC incidence in Eastern countries
EASL LiverTree™, Junqi Niu, 210719
Mindfulness based relapse prevention: beyond fighting against craving
EASL LiverTree™, Laure Gitzhoffen, 210703
Management of DAA Failures
EASL LiverTree™, Christoph Sarrazin, 210707
Symposium: NAFLD management in 2018: Chair
EASL LiverTree™, Sven Francque, 210710
Case finding and screening in populations at risk: Where do we stand?
EASL LiverTree™, Manal Abdelmalek, 210711
Risk factors for HCC in Europe – what is the role of NAFLD?
EASL LiverTree™, Helen Louise Reeves, 210718
The role of liver transplant coordinator in ensuring quality care
EASL LiverTree™, Lara Elshove, 210702
Nurses and Associates Forum: Quality care for people with liver disease: Chair
EASL LiverTree™, Michelle Clayton, 210699
Value of the nurse within the MDT in managing people with viral hepatitis
EASL LiverTree™, Colina Yim, 210701
Uncertainty management and psychological support to the patient and the caregiver
EASL LiverTree™, Barbara Kimbell, 210698
Nursing in end of life scenarios
EASL LiverTree™, Lynda Greenslade, 210697
Palliative care - beyond pain management
EASL LiverTree™, Aileen Marshall, 210696
Grand rounds - Case 2: Fatty liver in a lean patient
EASL LiverTree™, Claus Niederau, 210682
Grand rounds - Case 1: Fatty liver in a lean patient
EASL LiverTree™, Thomas Kaden-Janska, 210683
Grand rounds: Cirrhosis complications: Case Presenter
EASL LiverTree™, Barbara Lattanzi, 210680
Grand rounds: Fatty liver in a lean patient: Chair
EASL LiverTree™, Vlad Ratziu, 210681
Grand rounds: Primary biliary cholangitis: Case Presenter
EASL LiverTree™, Sara Lemoinne, 210689
Grand rounds: Severe alcoholic hepatitis: Case Presenter
EASL LiverTree™, Nikhil Vergis, 210692
Young investigators seminar: Palliative care in hepatology: an unmet need: Chair
EASL LiverTree™, Annalisa Berzigotti, 210693
A clinical case
EASL LiverTree™, Joana Carvalho, 210695
Nurses and Associates Forum: Involvement of nurses and associates in liver disease management: Panel Discussion
EASL LiverTree™, Session Speakers, 212537
NASH case study - conclusion
EASL LiverTree™, Fabienne Schumacher, 210677
Utilising the diabetes nurse specialist
EASL LiverTree™, Paula Mayo, 210676
Jean-Pierre Benhamou clinical state-of-the-art: Is it time to abandon the term cirrhosis?: Chair
EASL LiverTree™, Frank Tacke, 210668
Is it time to abandon the term cirrhosis?
EASL LiverTree™, Jaime Bosch, 210670
Optimising nutrition and lifestyle changes
EASL LiverTree™, Cecile Schwab, 210675
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study
EASL LiverTree™, Tarik Asselah, 210667
What is the role of the liver nurse?
EASL LiverTree™, Lynda Greenslade, 210674
Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
EASL LiverTree™, Gideon Hirschfield, 210666
NASH case study - introduction
EASL LiverTree™, Fabienne Schumacher, 210673
HEPAHEALTH: The Burden of liver disease in Europe
EASL LiverTree™, Helena Cortez-Pinto, 210665
International Recognition Awardee
EASL LiverTree™, Anna S. Lok, 210664
International Recognition Award Presentation
EASL LiverTree™, Marc Ghany, 210663
Recognition Awardee
EASL LiverTree™, Didier Samuel, 210662
Recognition Award Presentation
EASL LiverTree™, Daniel Shouval, 210661
Recognition Awardee
EASL LiverTree™, Mario U. Mondelli, 210660
Recognition Award Presentation
EASL LiverTree™, Michael P. Manns, 210659
MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
EASL LiverTree™, Stephen Harrison, 210658
Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: An extended 5-year follow-up
EASL LiverTree™, Jeong-Hoon Lee, 210657
General session II and award ceremony I: Chair
EASL LiverTree™, Frank Tacke, 210654
First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry
EASL LiverTree™, Thomas Berg, 210656
Breakfast morning rounds: NAFLD – How to achieve weight loss: Case Presentation and Discussion
EASL LiverTree™, Session Speakers, 212781
Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naïve participants
EASL LiverTree™, Tarik Asselah, 210648
Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection
EASL LiverTree™, Heiner Wedemeyer, 210647
Integrative molecular classification of extrahepatic cholangiocarcinoma
EASL LiverTree™, Robert Montal Roura, 210646
Sorafenib with versus without concurrent conventional transarterial chemoembolization (cTACE) in patients with advanced hepatocellular carcinoma (HCC): Results from a multicenter, open-label, randomized, controlled phase III STAH trial
EASL LiverTree™, Joong-Won Park, 210645
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study
EASL LiverTree™, Vlad Ratziu, 210644
Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the
EASL LiverTree™, Salvatore Piano, 210643
Final words
EASL LiverTree™, Tom Karlsen, 212312
World Hepatitis Alliance
EASL LiverTree™, Michael Ninburg, 212311
General session I and opening ceremony: Chair
EASL LiverTree™, Tom Karlsen, 210641
General session I and opening ceremony: Chair
EASL LiverTree™, Tilman Sauerbruch, 210642
PGC - Viral Hepatitis - HCV: Panel Discussion
EASL LiverTree™, Session Speakers, 212536
Pros and cons of transplanting HCV-infected organs
EASL LiverTree™, Marina Berenguer, 210635
The big picture: from a scientific finding to a clinical trial
EASL LiverTree™, Scott L. Friedman, 210640
HCV treatment in the immunosuppressed patient
EASL LiverTree™, Alessio Aghemo, 210634
Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis
EASL LiverTree™, Mujdat Zeybel, 210639
Removing patients from the transplant list with anti-HCV treatment
EASL LiverTree™, Norah Terrault, 210633
Liquid biopsy for liver fibrosis
EASL LiverTree™, Jelena Mann, 210638
Practical HCV treatment in patients with decompensated cirrhosis
EASL LiverTree™, Xavier Forns, 210632
In vivo antifibrotic therapy in the liver using cell-targeted nanohydrogel particles
EASL LiverTree™, Leonard Kaps, 210637
PGC - Viral Hepatitis - HCV: Case presentation
EASL LiverTree™, Kosh Agarwal, 210631
New drug delivery systems and diagnostics
EASL LiverTree™, Detlef SCHUPPAN, 210636
Characterization of TAA-specific CD8+ T cells in HCC patients
EASL LiverTree™, Catrin Tauber, 210630
Management of HBeAg-negative patients who stopped long-term treatment with nucleos(t)ide analogues
EASL LiverTree™, Thomas Berg, 210621
Adaptive immunity and immune checkpoint inhibition
EASL LiverTree™, Robert Thimme, 210629
Can we stop nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients?
EASL LiverTree™, Fabien Zoulim, 210620
PegIFN vs. oral therapy in HBeAg-negative CHB patients
EASL LiverTree™, Pietro Lampertico, 210619
Where do we stand on diagnosising HBV infection phase, and HBV-induced liver damage in HBeAg-negative carriers?
EASL LiverTree™, George Papatheodoridis, 210618
PGC - Viral Hepatitis: Chair
EASL LiverTree™, Heiner Wedemeyer, 210613
PGC - Viral Hepatitis - HBV: Case presentation
EASL LiverTree™, Rafael Esteban-Mur, 210617
PGC - Viral Hepatitis - HEV: Panel Discussion
EASL LiverTree™, Session Speakers, 212309
Treatment of hepatitis E
EASL LiverTree™, Nassim Kamar, 210606
A molecular perspective to new treatments in portal hypertension
EASL LiverTree™, Jordi GRACIA-SANCHO, 210611
Hepatitis E: natural history
EASL LiverTree™, Harry Dalton, 210605
Differential regulation of hepatic fibrosis by mesenchymal subpopulations
EASL LiverTree™, Ross Dobie, 210610
Diagnostics in HEV infection
EASL LiverTree™, Darius Moradpour, 210604
Drug targets in the dynamics of liver fibrosis
EASL LiverTree™, Neil Henderson, 210609
How to become infected with HEV in Europe
EASL LiverTree™, Robert A. de Man, 210603
The role of Pyruvate Kinase M2 in regulating liver inflammation
EASL LiverTree™, Wajahat Mehal, 210608
PGC - Viral Hepatitis - HEV: Case presentation
EASL LiverTree™, Sven Pischke, 210602
Modulating danger sensing at the interface to liver inflammation
EASL LiverTree™, Wajahat Mehal, 210607
Oral-gut-hepatic axis in cirrhosis
EASL LiverTree™, Chathur Acharya, 210601
PGC - Viral Hepatitis - HDV: Panel Discussion
EASL LiverTree™, Session Speakers, 212307
The role of liver transplantation in hepatitis delta
EASL LiverTree™, Didier Samuel, 210595
Liver disease drug targets in the gut microbiota
EASL LiverTree™, Jasmohan S Bajaj, 210600
The risk of decompensation and HCC development in patients with HDV-related cirrhosis
EASL LiverTree™, Grazia Niro, 210594
Nuclear receptor FXR and the enterokine FGF19 in hepatocarcinoma
EASL LiverTree™, Marica Cariello, 210599
Facts and controversies in treatment of hepatitis delta with PegIFNα
EASL LiverTree™, Cihan Yurdaydin, 210593
Bile acid signaling and related hormones: Lecture
EASL LiverTree™, Antonio Moschetta, 210598
Assessing liver fibrosis in hepatitis delta virus: invasive vs. non-invasive techniques. Is the liver biopsy still necessary as a diagnostic tool and in long-term surveillance?
EASL LiverTree™, Benjamin Heidrich, 210592
Case presentation
EASL LiverTree™, Mario Rizzetto, 210591
Glucose and lipid storage in metabolic and alcoholic fatty liver disease: what are the new drug targets?
EASL LiverTree™, Catherine Postic, 210596
HCC risk post-DAA treatment: a balanced perspective
EASL LiverTree™, Geoffrey Dusheiko, 210580
Combination of in vivo imaging and functional analysis reveals major changes in liver immunometabolic profile during newborn development
EASL LiverTree™, Brenda Naemi Lanza Nakagaki, 210590
Retreatment strategies in 2018
EASL LiverTree™, Jordan Feld, 210579
Imaging of cell-cell communication
EASL LiverTree™, Gustavo Menezes, 210589
Difficult-to-cure patients in 2018
EASL LiverTree™, Christophe Hezode, 210578
PGC - Viral Hepatitis - HCV: Case presentation
EASL LiverTree™, Alessandra Mangia, 210577
PGC - Viral Hepatitis - HBV: Panel Discussion
EASL LiverTree™, Session Speakers, 212304
How to manage pregnant women to minimize the risk of transmission
EASL LiverTree™, Henry Chan, 210576
Paired-cell sequencing reveals zonation of non-parenchymal liver cells
EASL LiverTree™, Keren Bahar Halpern, 210586
Spatial omics of the mammalian liver
EASL LiverTree™, Shalev Itzkovitz, 210585
When and how to treat a highly viraemic HBeAg-positive patient, and how to monitor and guide the treatment
EASL LiverTree™, Patrick Kennedy, 210575
Where do we stand with diagnosis of HBV infection phase and HBV-induced liver damage in HBeAg-positive carriers?
EASL LiverTree™, Maria Buti, 210574
PGC - Viral Hepatitis: Organiser
EASL LiverTree™, Francesco Negro, 210570
PGC - Viral Hepatitis - HBV: Case presentation
EASL LiverTree™, Anna S. Lok, 210573
Basic Science Seminar - Targetable pathways in liver disease: Chair
EASL LiverTree™, Prof. Frank Tacke & Dr. Helen Louise Reeves, 210581
Big data approaches to identify targetable pathways in liver cancer
EASL LiverTree™, Josep M Llovet, 210584
Therapy of dominant strictures in patients with PSC
EASL LiverTree™, Lars Aabakken, 210568
Research Think Tank - NAFLD: Targets and pharmacotherapy in NASH: Panel Discussion
EASL LiverTree™, Session Speakers, 210558
Endoscopic approaches for patients with refractory portal hypertensive bleeding
EASL LiverTree™, Andres Cardenas, 210567
Which patients will we be treating in 2020 and how will pharmacotherapy be tailored?
EASL LiverTree™, Elisabetta BUGIANESI, 210557
Skills in hepatology: Challenging issues in patients with liver disease undergoing invasive procedures: Chair
EASL LiverTree™, Andres Cardenas, 210565
Management of coagulation abnormalities and anticoagulants in patients with liver disease undergoing invasive procedures
EASL LiverTree™, Pierre-Emmanuel Rautou, 210566
Elastography is more than just fibrosis measurement
EASL LiverTree™, Giovanna Ferraioli, 210564
Targeting Nuclear Receptor Pathways in NASH (PPARs & FXR) - Risks
EASL LiverTree™, Michael Trauner, 210555
Can elastography be used in all liver diseases?
EASL LiverTree™, Matteo Rosselli, 210563
Targeting Nuclear Receptor Pathways in NASH (PPARs & FXR) - Benefits
EASL LiverTree™, Bart Staels, 210554
Shearwaves: the exchangeable or complementary method to measure elasticity?
EASL LiverTree™, Fabio Piscaglia, 210562
Lipotoxicity in NASH - from Disease Models to Novel Targets
EASL LiverTree™, Antonio Vidal-Puig, 210553
Transient elastography, essential part of liver diagnostics and follow up
EASL LiverTree™, Laurent Castera, 210561
Research Think Tank - NAFLD: Targets and pharmacotherapy in NASH: Chair
EASL LiverTree™, Quentin Mark Anstee, 210551
Skills in hepatology: Dissecting meaning and role of elastography in liver disease: Chair
EASL LiverTree™, Rob De Kengt, 210560
Future perspectives in HCC: The industry perspective
EASL LiverTree™, Gerold Meinhardt, 208049
What have we learn from failed trials and how do we design future trials?
EASL LiverTree™, Sandrine Faivre, 208048
Patient-derived models for drug discovery in liver cancer
EASL LiverTree™, Jens Marquardt, 208047
Roundtable: Novel approaches in immunotherapy: Discussion
EASL LiverTree™, Session Speakers, 208043
Immunotherapy in HCC: Current evidence and future perspective
EASL LiverTree™, Bruno Sangro, 208039
Role of immunology in HCC development and progression
EASL LiverTree™, Pablo Sarobe, 208038
Inflammation in liver tumorigenesis: Potential targets for immunotherapy
EASL LiverTree™, Eli Pikarsky, 208037
Tumour board #3: Clinical case discussion
EASL LiverTree™, Session Speakers, 208034
Assessment of systemic treatment activity by imaging
EASL LiverTree™, Maxime Ronot, 208033
Transarterial radioembolization: Role in the treatment of HCC
EASL LiverTree™, Jens Ricke, 208032
Approved systemic treatments for HCC: Which is the best treatment approach?
EASL LiverTree™, Maria Reig, 208031
Tumour board #3: Clinical case presentation
EASL LiverTree™, Marcus-Alexander Wörns, 208030
Tumour board #2: Clinical case discussion
EASL LiverTree™, Session Speakers, 208026
Liver transplantation - how to optimize patient selection?
EASL LiverTree™, Vincenzo MAZZAFERRO, 208025
Locoregional therapies in HCC: Ablation, transarterial therapies or combination of boths
EASL LiverTree™, Fabio Piscaglia, 208024
Expanding boundaries of surgical resection in HCC
EASL LiverTree™, Pietro Majno, 208023
Tumour board #2: Clinical case presentation
EASL LiverTree™, Pietro Majno, 208022
Roundtable discussion: How we can improve the current staging systems?
EASL LiverTree™, Session Speakers, 208019
Development of tumour makers for diagnosis, prognosis and tumour response prediction
EASL LiverTree™, Josep M Llovet, 208017
What is the role of biomarkers in diagnosis, prognosis and surveillance?
EASL LiverTree™, Fabio Piscaglia, 208016
Is biopsy adding clinically relevant information? The pathologist view
EASL LiverTree™, Valérie PARADIS, 208012
How to best diagnose HCC? Do we need hepatobiliary MR contrast agents? The radiologist view
EASL LiverTree™, Christophe Aubé, 208011
Is there a role for Contrast Enhanced Ultra Sound (CEUS) for improving the diagnostic accuracy of imaging techniques? The hepatologist view
EASL LiverTree™, Fabio Piscaglia, 208010
Early diagnostis of HCC: Which is the best strategy?: Chair
EASL LiverTree™, Alejandro Forner, 209134
FGF axis and FGFR inhibitors
EASL LiverTree™, Claus Hellerbrand, 208005
Epigenetic targets in hepatocarcinogenesis
EASL LiverTree™, Matias A Avila, 208003
The Hippo/YAP signalling pathway in liver tumour initiation and progression
EASL LiverTree™, Kai Breuhahn, 208004
Extent of intratumoural genomic diversity
EASL LiverTree™, Augusto Villanueva, 207998
Liquid biopsy for patient management: lesson from colon cancer
EASL LiverTree™, Pierre Laurent-Puig, 207997
Diagnostic and prognostic role of circulating microparticles in hepatobiliary cancers
EASL LiverTree™, Miroslaw Kornek, 207996
Immunotherapy in HCC and the hepatologist - what does the future multidisciplinary team look like?
EASL LiverTree™, Jordi Bruix, 207984
What is unique about fatty liver associated hepatocellular carcinoma?
EASL LiverTree™, Jean-Francois Dufour, 208534
Telomerase activation
EASL LiverTree™, Jean-Charles Nault, 208001
Genomic diversity in HCC: the TCGA experience
EASL LiverTree™, Lewis Roberts, 207987
Polyploidy in the liver: good or bad guy?
EASL LiverTree™, Chantal Desdouets, 207995
Tumour biology - stroma - immune cells - where are the best targets?
EASL LiverTree™, Jessica Zucman-Rossi, 207983
The changing epidemiology of HCC - how do we identify and screen patients at risk?
EASL LiverTree™, Jean-Francois Dufour, 207982
Welcome and Introduction
EASL LiverTree™, Jessica Zucman-Rossi, 207979
Concluding Remarks
EASL LiverTree™, Alessio Aghemo, 205065
Is the game over? The challenge of post-SVR management: Discussion
EASL LiverTree™, Session Speakers, 205064
The post-SVR HCC risk: life-long follow-up?
EASL LiverTree™, Alessio Aghemo, 205063
Alcohol and SVR: yes, how much, not at all
EASL LiverTree™, Nick SHERON, 205062
Beyond the liver: SVR and extrahepatic manifestations
EASL LiverTree™, Francesco Negro, 205061
Harm reduction and drug user health
EASL LiverTree™, Dagmar Hedrich, 205060
HCV reinfection following successful DAA therapy
EASL LiverTree™, PATRICK INGILIZ, 205059
Rise and fall of a virus
EASL LiverTree™, Antonio Craxi, 205056
Rise and fall of a virus: Introduction
EASL LiverTree™, Alessio Aghemo, 205951
How far are we from reaching the WHO targets of HCV elimination?: Panel Discussion
EASL LiverTree™, Session Speakers, 205055
The contribution from the industry
EASL LiverTree™, Michael Robertson, 205054
The contribution from the industry
EASL LiverTree™, Gregg Alton, 205053
The contribution from the industry
EASL LiverTree™, Fernando Tatsch, 205052
The role of payers
EASL LiverTree™, Ricardo Baptista Leite, 205051
The UK experience
EASL LiverTree™, Graham Foster, 205050
The Australian experience
EASL LiverTree™, Greg Dore, 205049
How far are we from reaching the WHO targets of HCV elimination?: Panel Discussion
EASL LiverTree™, Session Speakers, 206262
The role of patients’ associations
EASL LiverTree™, Tatjana Reić, 205048
What is required from a health systems perspective to achieve HCV elimination?
EASL LiverTree™, Jeffrey Lazarus, 205047
MPP model to scale up access to generic medicines with special focus on LMICs
EASL LiverTree™, Ludmila Maistat, 205046
Cost-effectiveness vs. affordability of HCV treatments
EASL LiverTree™, John Cairns, 205045
WHO elimination targets and the development of national viral hepatitis plans
EASL LiverTree™, Philippa Easterbrook & Sharon Hutchinson, 205766
Settings to facilitate HCV elimination: Discussion
EASL LiverTree™, Session Speakers, 205040
Clinical reality treatment landscape in Eastern Europe
EASL LiverTree™, Marieta Simonova, 205038
General practices, community health centres, and pharmacies
EASL LiverTree™, John Dillon, 205037
Drug, alcohol and psychiatry clinics
EASL LiverTree™, Martin Kaberg, 205036
Settings to facilitate HCV elimination: Chair
EASL LiverTree™, ANGELOS HATZAKIS, 205033
Prisons
EASL LiverTree™, Greg Dore, 205035
Treatment of HCV: Discussion
EASL LiverTree™, Session Speakers, 205032
Management of treatment failures
EASL LiverTree™, Massimo Puoti, 205031
Managing direct-acting antiviral therapy among people with HIV/HCV co-infection
EASL LiverTree™, Jürgen K. Rockstroh, 205030
Direct-acting interferon-free therapies among people who inject drugs
EASL LiverTree™, Olav Dalgard, 205029
Management of chronic HCV infection
EASL LiverTree™, Stefan Zeuzem, 205028
Management of acute HCV infection
EASL LiverTree™, Heiner Wedemeyer, 205027
Interventions to improve linkage of patients to HCV testing, care, and treatment: Discussion
EASL LiverTree™, Session Speakers, 205024
Engaging marginalized patients in the DAA era
EASL LiverTree™, Magdalena Harris, 205023
Scale-up of interventions to improve testing, care and treatment: lessons learned from HIV
EASL LiverTree™, Philippa Easterbrook, 205022
Diagnostic tools to improve HCV testing and diagnosis: where do we stand?
EASL LiverTree™, Jean-Michel Pawlotsky, 205021
Successful strategies to enhance HCV testing, linkage to care, and treatment
EASL LiverTree™, Jason Grebely, 205020
Epidemiology and prevention: Discussion
EASL LiverTree™, Session Speakers, 205017
Do we still need a vaccine for HCV?
EASL LiverTree™, Andrea Cox, 205016
Successful interventions for the prevention of HCV infection
EASL LiverTree™, Matthew Hickman, 205015
Morbidity and mortality associated with HCV infection
EASL LiverTree™, Sharon Hutchinson, 205014
Global HCV epidemiology
EASL LiverTree™, ANGELOS HATZAKIS, 205013
Patient experience
EASL LiverTree™, Andi Hüttenmoser, 205012
Welcome and introductory remarks
EASL LiverTree™, Francesco Negro, 205011
Epidemiology and prevention: Introduction
EASL LiverTree™, Prof. Jason Grebely and Dr. Dagmar Hedrich, 206299
Concluding remarks
EASL LiverTree™, Session Speakers, 203578
What is needed for drug approval? (Regulatory readouts from fibrosis studies)
EASL LiverTree™, Arun Sanyal, 201634
LOXL2: Lessons learned from the simtuzumab trials
EASL LiverTree™, Robert Myers, 201633
How to non-invasively assess fibrosis (serum, transient elastography, MRE)
EASL LiverTree™, Laurent Castera, 201631
Fibrosis as prognostically relevant signature: - do we have to care about differentiating NASH from NAFL (or just fibrosis)
EASL LiverTree™, Matias Ekstedt, 201630
Liver histology for biomarker and target discovery
EASL LiverTree™, Peter Schirmacher, 201624
Alcohol and nutrition in NAFLD progression to cancer
EASL LiverTree™, Claus Hellerbrand, 201623
Circulating tumor (stem) cells and liquid biopsy
EASL LiverTree™, Mathias Heikenwälder, 201622
MicroRNA (& lncRNA?) as biomarker and target
EASL LiverTree™, Cecilia Rodrigues, 201621
Academic overview: NASH as fertile soil for HCC, including challenge of pre-cirrhotic HCC
EASL LiverTree™, Jean-Francois Dufour, 201620
Impact of alive probiotics supplementation with absorbent smectite gel in NAFLD management: evidence from animals to randomized clinical studies.
EASL LiverTree™, Nazarii Kobyliak, 201617
Probiotic interventions
EASL LiverTree™, Vanessa Stadlbauer, 201616
Microbiota and FXR signaling in NAFLD and obesity, to induce or not to induce - that is the question
EASL LiverTree™, Annika Wahlström, 201615
Academic overview
EASL LiverTree™, Bernd Schnabl, 201614
ASBT inhibitors
EASL LiverTree™, Hanns-Ulrich Marschall, 201611
FGF-19 (FXR downstream target)
EASL LiverTree™, Matias A Avila, 201610
FXR - non- steroidal agonists
EASL LiverTree™, Nikolai Naoumov, 201609
FXR - steroidal agonists
EASL LiverTree™, Luciano Adorini, 201608
Bile acids as prognostic signature in NASH
EASL LiverTree™, Marco Arrese, 201607
Academic overview
EASL LiverTree™, Michael Trauner, 201606
Microparticles as biomarker
EASL LiverTree™, Ariel Feldstein, 201602
Caspase inhibitors: academic clinical
EASL LiverTree™, Jose Fernandez-Checa, 201601
Academic overview
EASL LiverTree™, Ali Canbay, 201600
VAP-1 inhibitors: Role of AOC3/VAP-1/SSAO in liver inflammation and small molecular AOC3 inhibitor approaches for the treatment of NASH.
EASL LiverTree™, Joerg RIPPMANN, 201597
Role of Inflammasomes in NAFLD
EASL LiverTree™, Fabio Marra, 201596
Oral immune therapy for NASH: A new class of drugs that target the gut immune system
EASL LiverTree™, Yaron Ilan, 201595
Industry perspective - inhibitors of CCR2 & 5
EASL LiverTree™, Eric Lefebvre, 201594
Academic overview
EASL LiverTree™, Frank Tacke, 201593
Omega-3 PUFA Modulate Lipogenesis, ER Stress, and Mitochondrial Dysfunction Markers in NASH - Proteomic and Lipidomic Insight
EASL LiverTree™, Claudia OLIVEIRA, 201590
Oxidative Stress, ER Stress and Mitochondrial Dysfunction: Academic Overview
EASL LiverTree™, Massimo Pinzani, 201588
Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor-ß (THR-ß) agonists
EASL LiverTree™, Rebecca Taub, 201585
Insulin sensitizers (metformin, TZDs/PPAR gamma) - in or out (including novel insulin, glucagon, GLP-1 fusion mimetics?
EASL LiverTree™, Christopher D. Byrne, 201584
Insulin resistance, insulin and hormonal signaling: Chair
EASL LiverTree™, Philip N Newsome, 201581
MRI, MR spectroscopy, CAP - does hepatic lipid content/composition matter
EASL LiverTree™, Manuel Romero Gomez, 201580
PPAR alpha and/or delta as pharmacological target (including discussion of FGF-21 (PPAR alpha downstream target) and brown/beige fat as PPAR/FGF21 target)
EASL LiverTree™, Bart Staels, 201579
PNPLPA3 and other genetic markers (TM6SF2) for risk stratification
EASL LiverTree™, Quentin Mark Anstee, 201578
Benefits/perils of promoting lipid combustion or inhibition of lipogenesis (DGAT, SCD, ANGPTL-3 inhibitors) in counteracting lipotoxicity
EASL LiverTree™, Leanne Hodson, 201577
Unmet needs in understanding pathogenesis and management of NAFLD and NASH
EASL LiverTree™, Vlad Ratziu, 201574
Opening and State of the Art Lecture: Chair
EASL LiverTree™, Michael Trauner, 201573
Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Luciano Adorini, 198294
Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Robert Ashley, 198086
Industry perspectives: Chair
EASL LiverTree™, Gyongyi Szabo, 198084
Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Patrick Colin, 198085
Discussion
EASL LiverTree™, Session Speakers, 200935
Which therapeutic targets will be the most attractive in the future?
EASL LiverTree™, Craig McClain, 198083
How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD
EASL LiverTree™, Aleksander Krag, 198081
Clinical trial design: What is the optimal plan of development from phase I to Phase III?
EASL LiverTree™, Alexandre Louvet, 198080
Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials
EASL LiverTree™, Mark Thursz, 198079
Patient characteristics and end-points in clinical trials for early ALD
EASL LiverTree™, Helena Cortez-Pinto, 198078
Discussion
EASL LiverTree™, Session Speakers, 198076
EMA process to validate end-points for drug approval: specific requirements for AH
EASL LiverTree™, Joachim Musaus, 198075
Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH
EASL LiverTree™, Ruby MEHTA, 198074
Cost and mortality attributed to Alcoholic Liver Disease
EASL LiverTree™, Jürgen Rehm, 198073
Discussion
EASL LiverTree™, Session Speakers, 198071
Alcohol relapse after transplantation: does it matter?
EASL LiverTree™, Georges-Philippe PAGEAUX, 198070
Post-transplant complications/what is specific for ALD
EASL LiverTree™, Patrizia Burra, 198069
Early liver transplantation in AH - Pro and Con debate: I favour broader use of early liver transplantation in AH
EASL LiverTree™, Philippe MATHURIN, 198068
Early liver transplantation in AH - Pro and Con debate: I do not favour broader use of early liver transplantation for AH
EASL LiverTree™, Michael Lucey, 198067
SIRS and management of infection in AH
EASL LiverTree™, Ramon Bataller, 198066
Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival
EASL LiverTree™, Patrick Kamath, 198065
State-of-the-Art Lecture: Molecular pathways in hepatocellular carcinoma
EASL LiverTree™, Michael Karin, 198063
Discussion
EASL LiverTree™, Session Speakers, 198062
Non-invasive assessment including imaging in early versus advanced ALD
EASL LiverTree™, Laurent Castera, 198061
Liquid Biopsy and Biomarkers is a Diagnostic Measure in Surrogate End-Point in Alcoholic Hepatitis
EASL LiverTree™, Vijay Shah, 198060
Liver histology and AH/ALD - what is its role?
EASL LiverTree™, Dina TINIAKOS, 198059
Alcohol use disorder: diagnosis and management
EASL LiverTree™, Giovanni Addolorato, 198057
Animal models of ALD and alcoholic hepatitis:Intragastric alcohol feeding model for identifying key therapeutic pathways
EASL LiverTree™, Hidekazu Tsukamoto, 198054
Animal models of ALD and alcoholic hepatitis: I favour the NIAAA model for targeting the key therapeutic pathways
EASL LiverTree™, Bin Gao, 198053
Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD?
EASL LiverTree™, Anna Mae Diehl, 198052
Inflammation as a driver of ALD
EASL LiverTree™, Gyongyi Szabo, 198050
Discussion
EASL LiverTree™, Session Speakers, 198049
From microbiome to intestinal inflammation in ALD
EASL LiverTree™, Bernd Schnabl, 198048
Role of miRNAs in the sensitization of TLR4 signaling by ethanol
EASL LiverTree™, Laura E. Nagy, 198047
Genetics of ALD: What do we learn from the risk loci about the disease?
EASL LiverTree™, Jochen Hampe, 198044
Burden and epidemiology of alcohol-related liver diseases in Europe and North America
EASL LiverTree™, David Leon, 198042
Welcome and opening remarks
EASL LiverTree™, Philippe MATHURIN, 198039
Welcome and opening remarks
EASL LiverTree™, Gyongyi Szabo, 198040
Concluding Remarks
EASL LiverTree™, Peter L Jansen, 183780
Best of EASL Monothematic Conference: Cholangiocytes in health and disease: from basic science to novel treatments
EASL LiverTree™, Dr. J.M. Banales, Prof. Dr. P.L. Jansen, Prof. N.F. Larusso, Dr. M. Marzioni, 186698
Principles of value based medicine as applied to cholangiopathies
EASL LiverTree™, Mario Strazzabosco, 183778
Endpoints in the designing of clinical trials
EASL LiverTree™, Cyriel Ponsioen, 183777
Cell transplantation
EASL LiverTree™, Domenico Alvaro, 183776
Cholestatic drug induced liver injury
EASL LiverTree™, Raúl J Andrade, 183775
The future of therapy for cholangiopathies
EASL LiverTree™, Michael Trauner, 183774
Assessment of hepatic secretion function with 11C-cholylsarcosine PET/CT
EASL LiverTree™, Michael Soerensen, 183773
Biomarkers for cholangiopathies and cholangiocarcinoma
EASL LiverTree™, Daniel Gotthardt, 183772
The endoscopist and malignant and non-malignant biliary obstructions
EASL LiverTree™, Stephen Pereira, 183769
Cholangiocarcinoma: Epidemiological trends and clinical management
EASL LiverTree™, Shahid A Khan, 183768
Genetics of familial cholangiopathies
EASL LiverTree™, Frank Lammert, 183767
Cholangiopathies in children
EASL LiverTree™, Richard Thompson, 183766
Tumour stroma in cholangiocarcinoma: A novel therapeutic target
EASL LiverTree™, Joachim C. Mertens, 183763
Chemoresistance and chemosensitization in cholangiocarcinoma
EASL LiverTree™, Jose Marin, 183762
Stem cell origin of cholangiocarcinoma
EASL LiverTree™, Tania Roskams, 183761
Target molecules in cholangiocarcinoma cells
EASL LiverTree™, Gregory Gores, 183760
BBA AWARD
EASL LiverTree™, Ronald Oude Elferink, 184937
IgG4 cholangiopathy, a new entity
EASL LiverTree™, Ulrich Beuers, 183757
Bile acid homeostasis and immunity of the liver
EASL LiverTree™, Christoph Schramm, 183756
How the biliary tree maintains immune tolerance?
EASL LiverTree™, Xiong Ma, 183755
Mucosal immunity of the biliary tree in normality and disease
EASL LiverTree™, David Adams, 183754
The bile acid receptor TGR5 regulates paracellular permeability and protects the liver through an impact on the tight junction protein JAM-A
EASL LiverTree™, Grégory Merlen, 183751
Chronic treatment with clinic dose of metformin completely reverses the epithelial to mesenchymal transition (EMT) in human intrahepatic cholangiocarcinomas (iCCAs) by activated AMPK / Foxo3a pathway
EASL LiverTree™, Sabina Di Matteo, 183750
Inhibition of Src tyrosine kinase restores CFTR function in cystic fibrosis cholangiocytes derived from human induced pluripotent stem cells (iPSC) and improves the response to CFTR potentiators and correctors used in therapy
EASL LiverTree™, Romina Fiorotto, 183749
The role of ageing in the pathophysiology of the biliary epithelium: identification of a molecular profile
EASL LiverTree™, Luca Maroni, 183748
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
EASL LiverTree™, Ander Arbelaiz, 183747
Bile acid-induced nephropathy
EASL LiverTree™, Peter Fickert, 183745
Heart and bile acids
EASL LiverTree™, Catherine Williamson, 183744
The molecular mechanism of cholestatic itch
EASL LiverTree™, Ronald Oude Elferink, 183743
Bile acids, FGF15/19 and liver regeneration: from mechanisms to clinical applications
EASL LiverTree™, Matias A Avila, 183741
TGR5 in physiology and disease
EASL LiverTree™, Verena Keitel, 183740
Gut and liver interactions
EASL LiverTree™, Antonio Moschetta, 183739
Pathogenesis and 3D structure of biliary fibrosis
EASL LiverTree™, Massimo Pinzani, 183735
Genetics and mechanisms of biliary cystogenesis: Impact in the clinical practice
EASL LiverTree™, Joost PH Drenth, 183734
Non coding-RNAs and extracellular vesicles
EASL LiverTree™, Jesus M. Banales, 183733
Animal models of biliary injury and altered bile acid metabolism
EASL LiverTree™, Luca Fabris, 183731
Repopulating the biliary tree from the peribiliary glands
EASL LiverTree™, Robert Porte, 183727
Development of the biliary tree
EASL LiverTree™, Frederic Lemaigre, 183725
3D Anatomy of the biliary tree: Intravital two-photon based functional imaging of bile salt transport in cholestasis - pathophysiology of bile infarct formation
EASL LiverTree™, Jan Hengstler, 183724
State-of-the-Art lecture: Cholangiocyte pathobiology: Past, present and future
EASL LiverTree™, Nicholas LaRusso, 183721
Welcome and introductory remarks
EASL LiverTree™, Jesus M. Banales, 183718
Welcome and introductory remarks
EASL LiverTree™, Marco Marzioni, 183720
Best of Autoimmune and Cholestatic Liver Disease from ILC2017
EASL LiverTree™, Prof. Michael Manns and Dr. Gideon Hirschfield, 182281
General session IV: Conclusions
EASL LiverTree™, Tom Karlsen, 182109
Viral hepatitis
EASL LiverTree™, Heiner Wedemeyer, 173802
Metabolic and cholestatic diseases
EASL LiverTree™, Vlad Ratziu, 173801
Best of Liver Tumours from ILC2017
EASL LiverTree™, Dr. Bruno Sangro and Prof. Peter Schirmacher, 182280
General session IV: Chair
EASL LiverTree™, Francesco Negro, 173799
General hepatology (including tumours and liver transplantation)
EASL LiverTree™, Jean-Francois Dufour, 173800
Control of cholestatic liver diseases by intestinal nuclear receptors
EASL LiverTree™, Antonio Moschetta, 173797
Control of immune function by the intestine through the nuclear receptor RORgt
EASL LiverTree™, David Withers, 173796
Best of Nurses and Associates Forum from ILC2017
EASL LiverTree™, Kathrin Husi and Pam O'Donoghue, 182279
Microbiota-intestine interactions control of NASH
EASL LiverTree™, Frank J. Gonzalez, 173795
Best of Cirrhosis and Complications from ILC2017
EASL LiverTree™, Prof. Emmanuel Tsochatzis and Dr. Joan Genesca Ferrer, 182278
Primary sclerosing cholangitis: endoscopic challenges in diagnosis and treatment
EASL LiverTree™, Cyriel Ponsioen, 173792
Viral Hepatitis
EASL LiverTree™, Alessio Aghemo, 173788
Primary biliary cholangitis: treatment beyond UDCA
EASL LiverTree™, Michael Trauner, 173791
General Hepatology (including tumors and liver transplantation)
EASL LiverTree™, Philippe MATHURIN, 173787
Symposium - Challenges in autoimmune and cholestatic liver diseases: Chair
EASL LiverTree™, Christoph Schramm, 173789
Immunosuppressive treatment in autoimmune hepatitis: duration, intensity and alternatives
EASL LiverTree™, Michael A Heneghan, 173790
Best of Viral Hepatitis from ILC2017
EASL LiverTree™, Prof. Heiner Wedemeyer and Prof. Fabien Zoulim, 182277
Basic and translational science
EASL LiverTree™, Jesus M. Banales, 173786
Metabolic and cholestatis
EASL LiverTree™, Quentin Mark Anstee, 173785
Best of Alcoholic and Metabolic Liver Disease from ILC2017
EASL LiverTree™, Prof. Elisabetta Bugianesi and Dr. Ramon Bataller, 182276
CPG Session HCV: Q&A
EASL LiverTree™, Session Speakers, 182304
CPG Session HCV: Treatment failures, resistance and retreatment
EASL LiverTree™, Christoph Sarrazin, 173782
CPG Session HCV: HCC recurrence/occurrence post-DAA therapy
EASL LiverTree™, Geoffrey Dusheiko, 173783
CPG Session HCV: Best timing of treatment in patients with decompensated liver disease
EASL LiverTree™, Robert Fontana, 173781
CPG Session HCV: Treatment of Patients with Chronic Kidney Disease
EASL LiverTree™, Alessio Aghemo, 173784

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings